| Patent application number | Description | Published |
|---|
| 20090012159 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS - The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C | 01-08-2009 |
| 20090274761 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN - The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C | 11-05-2009 |
| 20110165247 | DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF A ROTIGOTINE BASE - The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient. | 07-07-2011 |
| Patent application number | Description | Published |
|---|
| 20080196553 | Electrical Device, in Particular an Electrical Hand-Held Power Tool - The invention is based on an electric device, in particular an electric hand tool, having a removable power supply unit ( | 08-21-2008 |
| 20090286143 | BATTERY PACK - A battery pack according to the invention has a housing, at least one rechargeable battery cell, and at least one temperature sensor that is attachable in a thermally conductive fashion to the rechargeable cell. At least one clamping element is provided, which cooperates with the temperature sensor in such a way that it is possible to attach the temperature sensor to the rechargeable cell in a thermally conductive fashion. | 11-19-2009 |
| 20100209759 | BATTERY PACK - The invention describes a battery pack having a housing and at least one battery cell. According to the invention, also provided are elements which compensates for tolerance variations of the battery cell(s). The tolerance compensation elements include at least one spreading element which is arranged in an intermediate space between at least two battery cells and/or between one battery cell and the housing. | 08-19-2010 |
| 20100265661 | HEAT SINK OF AT LEAST ONE ELECTRONIC COMPONENT - The invention relates to a cooling body of at least one electrical component. According to the invention, a first cooling body section is designed as a spring and a contact surface is provided on the first cooling body section, between the cooling body and the at least one component. | 10-21-2010 |
| Patent application number | Description | Published |
|---|
| 20090022798 | FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS - The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release. | 01-22-2009 |
| 20090148531 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 06-11-2009 |
| 20100081715 | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof a other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically ceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 04-01-2010 |
| 20110015216 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-20-2011 |
| Patent application number | Description | Published |
|---|
| 20090220596 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix - A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms. | 09-03-2009 |
| 20090274731 | PRODUCTION OF ENVELOPED PHARMACEUTICAL DOSAGE FORMS - A process for at least partially enveloping a pharmaceutical dosage form, in which the dosage form is surrounded by a shrinkable film, and the film is subsequently shrunk is described. | 11-05-2009 |
| 20090302493 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 12-10-2009 |
| 20090311414 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 12-17-2009 |
| 20100119583 | SOLID DOSAGE FORM WITH A FILM CONTAINING AN ACTIVE SUBSTANCE, AS WELL AS ITS METHOD OF PRODUCTION - The present invention relates to a solid dosage form with at least one film ( | 05-13-2010 |
| 20100247635 | PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME - A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake. | 09-30-2010 |
| 20100297223 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION - A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4. | 11-25-2010 |
| 20110123652 | SELF-EMULSIFYING ACTIVE SUBSTANCE FORMULATION AND USE OF THIS FORMULATION - The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media. | 05-26-2011 |
